Oragenics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.4M
- Price
- $0.525
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.78%
- Volume
- 56.5K
About
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Quick stats
Shares outstanding4.5M
Computed float3.4M
Float / shares76.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001174940
Websitehttps://www.oragenics.com
AI Summary
AI-generated1/10
standardbullishclinical trial
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Oragenics achieved full activation of its Australian Phase IIa clinical trial network for ONP-002, with all three planned sites now enrolling participants.
Alfred Health enrolled the first participant, and zero serious adverse events have been reported to date, with a data readout targeted for the fourth quarter of 2026.
The company also submitted a Type B meeting request to the FDA to facilitate guidance on its planned U.S. clinical development program and IND submission.